Navigation Links
Clostridium difficile Infection: Current Challenges and Controversies
Date:1/20/2009

Complimentary Continuing Education Virtual Lecture and Podcast for Healthcare Professionals

VOORHEES, N.J., Jan. 20 /PRNewswire/ -- Current education about Clostridium difficile infection (CDI) is critical for several reasons. The epidemiology of CDI is changing and has been marked by increasing rates and more severe disease. In addition, the epidemic strain continues to be reported in an expanding list of states across the United States and worldwide.

To address the need for current education on CDI risk factors, diagnostic techniques, and optimal treatment strategies, Robert Michael Educational Institute LLC (RMEI) and Postgraduate Institute for Medicine (PIM) are jointly sponsoring a complimentary continuing education virtual lecture and podcast for physicians, pharmacists, and nurses titled Clostridium difficile Infection: Current Challenges and Controversies. This activity is supported by an educational grant from ViroPharma Incorporated.

The information contained in this virtual lecture and podcast was originally presented as a live symposium during the 2008 ICAAC/IDSA Joint Meeting. The chairperson for this program is international expert in infectious diseases, Dale N. Gerding, MD, FACP, FIDSA, Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois, and Associate Chief of Staff for Research and Development at Hines Veterans Affairs Hospital in Hines, Illinois. Other faculty include experts in infectious diseases, gastroenterology, and infection control from leading medical institutions across the United States.

Healthcare professionals can visit www.rmei.com/CDI052 to access this virtual lecture and podcast.

"Robert Michael Educational Institute LLC recognizes that continuing education plays a crucial role in the provision of quality healthcare and is dedicated to offering professionals meaningful opportunities for lifelong learning," says President and CEO, Robert M. Colleluori.

RMEI is a medical education company that specializes in independent, accredited, and nonaccredited education. The goal of all accredited RMEI educational offerings is to promote a spirit of lifelong learning and continuous professional development. RMEI works closely with medical experts to design activities that improve diagnosis and treatment. These activities include national and international symposia, teleconferences, live meetings, enduring print materials, and interactive Internet programs.

For other educational opportunities, please visit www.rmei.com.


'/>"/>
SOURCE Robert Michael Educational Institute LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
2. Putting a new spin on current research
3. New small-scale generator produces alternating current by stretching zinc oxide wires
4. Solos Endoscopy, Inc. in Final Stages to Upgrade Pink Sheet Status from Limited to Current Information
5. Huifeng Bio-Pharmaceutical (HFGB) Provides Update on Current Business and COS Certification
6. 72% of Women Are Dissatisfied With Their Current Treatment of Vaginal Infection, Survey Finds
7. Avastin Used in Combination with Drugs from Bristol-Myers Squibb Has Advantages in Survival Rates Over the Current Sales-Leading Therapy for Advanced Ovarian Cancer
8. Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity
9. National Stem Cell Holding, Inc. Has Engaged BMA Securities to Assist and Advise the Company With Its Current Capital Raise of $3,500,000
10. GlaxoSmithKline Consumer Healthcare Recommends Maintaining FDAS Current Two-Class Drug System
11. First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016 Eutilex Co. Ltd. today announced ... $18.9M) Series A financing. This financing round included participation ... and SNU Bio Angel. This new funding brings the ... (US $27.7M) since its founding in 2015. ... development and commercialization of its immuno-oncology programs, expand its ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... phase I/II dose escalation and expansion clinical trial for its lead drug candidate, ... The purpose of the trial was to determine the safety, antitumor activity, and ...
(Date:12/7/2016)... Dec. 7, 2016 Neogen Corporation (NASDAQ: ... Dan Kephart as its chief science officer ... assume his responsibilities at Neogen effective Jan. 1. ... for the agribusiness unit of Thermo Fisher Scientific, as ... Life Technologies. His extensive industry experience also includes the ...
(Date:12/7/2016)... OTTAWA, Ontario , Dec. 7, 2016 /PRNewswire/ ... partnership with General Atomics (GA), welcome today,s award ... National Nuclear Security Administration (NNSA) of the Phase ... its project with Nordion and the University of ... Phase II funding will support the establishment of ...
Breaking Biology Technology:
(Date:6/21/2016)... Columbia , June 21, 2016 ... to the new role of principal product architect ... named the director of customer development. Both will ... chief technical officer. The moves reflect NuData,s strategic ... in response to high customer demand and customer ...
(Date:6/16/2016)... SAN FRANCISCO , June 16, 2016 /PRNewswire/ ... Market size is expected to reach USD ... report by Grand View Research, Inc. Technological proliferation ... and banking applications are expected to drive the ... ) , The development of ...
(Date:6/9/2016)... control systems is proud to announce the introduction of fingerprint attendance control software, allowing ... are actually signing in, and to even control the opening of doors. ... ... ... Photo - http://photos.prnewswire.com/prnh/20160609/377487 ...
Breaking Biology News(10 mins):